The main anticoagulant action of heparin mainly depends on antithrombin ⅲ. After heparin and antithrombin ⅲ bind themselves, the configuration of antithrombin ⅲ can develop and change, and can combine with a variety of coagulation function factors to inhibit these coagulation factors, so as to achieve the purpose of anticoagulation. The specific mechanism is analyzed as follows:
Heparin is originally isolated from the liver, hence the name heparin. Heparin is a mucopolysaccharide sulfate, alternating with D-glucosamine, L-eiduronic acid, and D-glucuronic acid. Heparin has a strong anticoagulant effect, so the physiological state of the blood contains almost no heparin. The coagulation time and partial thrombin time were significantly prolonged within 10 minutes after intravenous heparin administration, and the effect could be maintained for 3 * 4 hours.
The combination of heparin with antithrombin iii can change the antithrombin configuration and expose the active site of the antithrombin iii. After exposure, heparin is better able to bind to clotting factors, thereby inhibiting clotting factors. Of these, antithrombin III can form a complex with thrombin, resulting in a weakening of thrombin, while heparin accelerates this reaction thousands of times faster. When thrombin is weakened, the conversion of fibrinogen to fibrin is weakened and the coagulation time is greatly prolonged. In addition, heparin inhibits platelet aggregation, a mechanism that may also work by inhibiting thrombin action.
Heparin Sodium API Supplier: Clinical application of Heparin
Because heparin has a good anticoagulant effect, it is mainly applied to some thrombosis related diseases in enterprises, such as deep vein thrombosis, myocardial infarction, pulmonary embolism, peripheral artery thrombosis and blood hypercoagulability through various social reasons, mainly to prevent the formation and expansion of thrombosis. However, heparin also has some disadvantages, such as the risk of bleeding, the use of different doses need to be more strict, and it may directly lead to thrombocytopenia in patients, and has its own certain risk of allergy.
Heparin Sodium API Supplier: Low molecular weight Heparin
Low molecular weight heparin is lower than ordinary heparin, and it can be directly isolated from ordinary heparin or degraded from ordinary heparin. The characteristic of low molecular weight heparin is that it selectively inhibits the activity of activated clotting factor X and has little effect on thrombin and other clotting factors. Therefore, compared with ordinary heparin, it has a more precise target inhibition effect.
Compared with ordinary heparin, the clinical application of low molecular weight heparin has the advantages of easy control of anticoagulant determination, small individual differences, generally no monitoring of anticoagulant activity, low toxicity, safety, and long acting time.